Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 (Reuters) - U.S. biotech company Momenta

Pharmaceuticals Inc said on Tuesday its experimental

biosimilar version of AbbVie Inc's top-selling

autoimmune drug, Humira, met the main goal in a late-stage trial

involving patients with a form of psoriasis.

Read more